MedPath

Comparing the starting time of tacrolimus administration in management of kidney transplant recipients

Phase 3
Conditions
Kidney transplant.
Kidney transplant status
Registration Number
IRCT201604253043N11
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
50
Inclusion Criteria

All patients who underwent the first of Deceased donor or Living donor kidney transplantation in Imam Khomeini Hospital Complex, Tehran, Iran ; Age is = 14 y ; Patients who receive thymoglobulin induction ; Patients who receive Mycophenolate and Prednisone plus Tacrolimus as immunosuppressive regimen.
Exclusion criteria: Patients with unstable cardiac, hepatic, pulmonary functions after kidney transplantation ; Patients who have multiple organ transplantation ; Patients with known malignancy.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recipient's serum creatinine. Timepoint: Before the transplantation, every 6 hours on the first day of transplant, then daily during hospitalization, then weekly until the end of the first month after transplant, then monthly until the end of the third month after transplat. Method of measurement: Blood samples in laboratories in milligrams / deciliter.;Recipient's urine output. Timepoint: Before transplantation and daily during hospitalization. Method of measurement: Graduated container in ml/day.;Incidence of DGF. Timepoint: During first week after transplantation. Method of measurement: Need for dialysis.
Secondary Outcome Measures
NameTimeMethod
Graft survival. Timepoint: First three months after transplantation. Method of measurement: Number of functioning kidney.;The incidence of acute rejection. Timepoint: During the first three months after transplantation. Method of measurement: Based on function of transplanted kidney.
© Copyright 2025. All Rights Reserved by MedPath